Aclaris Therapeutics, Inc.

NASDAQ:ACRS

Biotechnology

Healthcare
$3.50 +0.57%

+$0.03 today

Market cap
$555.14M
Beta
0.80
P/E (TTM)
-8.2
EPS (TTM)
-$0.54
52W Low $1.34High $5.15

Volume 2.94M

Average 1.40M

ACRS Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Aclaris Therapeutics, Inc.NASDAQ: ACRS

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q1 FY2026 weighted avg shares of 128.81M shares rose 5.2% year over year, behind the +37.8% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 5.0% from the prior quarter. Over 3 fiscal years it compounded at +23.4% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +5.2% toward the trailing-twelve-month pace of +37.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
128.81M+5.0% QoQ
Last fiscal yearDec 2025
122.66M+58.7% YoY
LTMMar 2026
124.17M+37.8% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+5.2%——
1 year+58.7%——
3-year CAGR+23.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
122.66M USD
Year-over-year change
+58.7%
4-year CAGR
+21.3%

Weighted Avg Shares vs competitors

How ACRS compares with its peers on the latest reported figures

  • ACRS's LTM Mar 2026 weighted avg shares of 124.17M shares is the highest of the 10 companies compared; the peer median is 43.03M shares.
  • Its year-over-year change of +37.8% is the 3rd highest of 9, against a peer median of +2.5%.
  • Over three fiscal years its annual growth of +23.4% compares with a peer median of +22.5%.
ACRS Competitors Peer median
Weighted Avg Shares for ACRS and competitors
Company Period LTM YoY 3-year CAGR
ACRSAclaris Therapeutics, Inc.LTM Mar 2026124.17M +37.8%+23.4%
ALMSAlumis Inc. Common StockLTM Jun 2026115.39M +93.7%+384.0%
IFRXInflaRx N.V.LTM Mar 202668.77M +14.6%+15.0%
MLTXMoonLake ImmunotherapeuticsLTM Mar 202665.6M +4.1%+30.0%
ALDXAldeyra Therapeutics, Inc.LTM Mar 202660.16M +1.0%+0.9%
ATTOAttovia Therapeutics, Inc.FY202543.03M +0.0%—
AGMBAgomAb Therapeutics N.V. American Depositary SharesFY202436.24M +0.0%—
ANABAnaptysBio, Inc.LTM Mar 202628.59M -2.5%-0.4%
IMUXImmunic, Inc.LTM Mar 202619.58M +98.7%+69.8%
TRAXFirst Tracks Biotherapeutics IncFY20250 ——
ODTXOdyssey Therapeutics, Inc.—— ——
Peer median (excluding ACRS) 43.03M+2.5%+22.5%

Competitors are the stored peer set for ACRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.76M29.75M31.25M18.72M7.83M
Cost of Revenue4.71M11.96M18.08M2.79M2.09M
Gross Profit2.05M17.79M13.17M15.93M5.74M
Gross Margin30.3%59.8%42.1%85.1%73.3%
Research & Development43.81M77.81M98.38M33.59M52.65M
Selling, General & Admin23.62M25.13M31.1M22.2M21.97M
Operating Expenses91.77M107.65M110.53M157.86M82.11M
Depreciation & Amortization923K797K863K807K454K
EBITDA(64.46M)(84.36M)(115.45M)(51.72M)(64.47M)
EBITDA Margin-953.4%-283.5%-369.5%-276.3%-823.8%
Operating Income(89.72M)(89.85M)(97.36M)(141.93M)(76.38M)
Operating Margin-1327.1%-302.0%-311.6%-758.2%-975.9%
Interest Income0007.95M7.64M
Interest Expense00000
Other Income / Expenses(1.14M)2.95M8.51M9.87M11.45M
Income Before Tax(90.87M)(86.91M)(88.85M)(132.07M)(64.92M)
Pre-Tax Margin-1344.0%-292.1%-284.3%-705.5%-829.6%
Income Tax Expense00(367K)00
Net Income(90.87M)(86.91M)(88.48M)(132.07M)(64.92M)
Net Margin-1344.0%-292.1%-283.1%-705.5%-829.6%
EPS (Basic)(1.60)(1.33)(1.27)(1.71)(0.53)
EPS (Diluted)(1.60)(1.33)(1.27)(1.71)(0.53)
Weighted Avg Shares56.73M65.21M69.81M77.3M122.66M
Weighted Avg Shares (Diluted)56.73M65.21M69.81M77.3M122.66M

Aclaris Therapeutics, Inc.

NASDAQ:ACRS

Intrinsic Alpha fair value

Locked

Current Price

$3.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.